BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+64.6%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$1.62B
AUM Growth
+$1.62B
(+51%)
Cap. Flow
+$243M
Cap. Flow
% of AUM
14.99%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
65
New
8
Increased
19
Reduced
26
Closed
8
Top Buys
| 1 |
argenx
ARGX
|
$82.2M |
| 2 |
Repare Therapeutics
RPTX
|
$60.3M |
| 3 |
Arcus Biosciences
RCUS
|
$45.6M |
| 4 |
Celldex Therapeutics
CLDX
|
$35.6M |
| 5 |
Protagonist Therapeutics
PTGX
|
$29.6M |
Top Sells
| 1 |
Cytokinetics
CYTK
|
$46.4M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$30.8M |
| 3 |
SWTX
SpringWorks Therapeutics
SWTX
|
$20.2M |
| 4 |
Revolution Medicines
RVMD
|
$18.9M |
| 5 |
Mersana Therapeutics
MRSN
|
$13.8M |
Sector Composition
| 1 | Healthcare | 97.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
| $96M | 5.92% | 2,286,891 -480,739 | -17% | -$20.2M |
|
|
PRNB
2
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $88.8M | 5.47% | 1,484,674 -98,921 | -6% | -$5.91M |
|
|
3
argenx
ARGX
$43.6B
| $87.8M | 5.42% | 390,000 +365,000 | +1,460% | +$82.2M |
|
|
4
Ionis Pharmaceuticals
IONS
$6.79B
| $83.9M | 5.17% | 1,422,842 -521,675 | -27% | -$30.8M |
|
5
Merus
MRUS
$4.98B
| $81.9M | 5.05% | 5,090,571 +1,545,917 | +44% | +$24.9M |
|
6
Xoma
XOMA
$392M
| $79.6M | 4.91% | 4,026,157 +1,252,772 | +45% | +$24.8M |
|
7
AC Immune
ACIU
$205M
| $76.2M | 4.7% | 11,318,758 -23,747 | -0.2% | -$160K |
|
8
Xencor
XNCR
$580M
| $67M | 4.13% | 2,068,098 +378,798 | +22% | +$12.3M |
|
|
9
Repare Therapeutics
RPTX
$71.7M
| $60.3M | 3.72% | +1,944,546 | New | +$60.3M |
|
10
Replimune Group
REPL
$422M
| $57.5M | 3.55% | 2,315,053 +339,844 | +17% | +$8.45M |
|
|
FPRX
11
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $48.7M | 3% | 7,988,053 +205,052 | +3% | +$1.25M |
|
|
12
Arcus Biosciences
RCUS
$1.13B
| $46.6M | 2.87% | 1,882,722 +1,844,148 | +4,781% | +$45.6M |
|
13
IDEAYA Biosciences
IDYA
$2.15B
| $45.9M | 2.83% | 3,226,769 +1,941,940 | +151% | +$27.6M |
|
14
Kura Oncology
KURA
$686M
| $45.2M | 2.79% | 2,775,882 +341,186 | +14% | +$5.56M |
|
15
Xenon Pharmaceuticals
XENE
$2.98B
| $44.1M | 2.72% | 3,516,851 +842,513 | +32% | +$10.6M |
|
|
16
Protagonist Therapeutics
PTGX
$3.67B
| $41.8M | 2.58% | 2,367,288 +1,674,858 | +242% | +$29.6M |
|
|
CALA
17
DELISTED
Calithera Biosciences, Inc
CALA
| $37.4M | 2.31% | 7,090,638 -2,469,004 | -26% | -$13M |
|
18
Syndax Pharmaceuticals
SNDX
$1.41B
| $36.6M | 2.26% | 2,470,678 +330,894 | +15% | +$4.9M |
|
|
19
Celldex Therapeutics
CLDX
$1.47B
| $35.6M | 2.2% | +2,740,000 | New | +$35.6M |
|
|
MTEM
20
DELISTED
Molecular Templates, Inc.
MTEM
| $29.6M | 1.83% | 2,149,057 -701,214 | -25% | -$9.67M |
|
21
AnaptysBio
ANAB
$569M
| $28.9M | 1.78% | 1,294,401 -395,836 | -23% | -$8.84M |
|
|
CBIO
22
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $27.2M | 1.68% | 7,244,262 -117,539 | -2% | -$442K |
|
23
Immunovant
IMVT
$2.56B
| $26.5M | 1.63% | 1,088,479 +88,483 | +9% | +$2.15M |
|
24
CytomX Therapeutics
CTMX
$336M
| $26M | 1.6% | 3,115,537 -806,436 | -21% | -$6.72M |
|
|
25
Revolution Medicines
RVMD
$7.1B
| $25.2M | 1.55% | 798,286 -599,784 | -43% | -$18.9M |
|